Market News AIOpen the app

Q/C Technologies, Inc. has signed an important agreement with PharmaCyte Biotech, Inc.

New sharesRead the original at SEC EDGAR
Good for QCLS

Q/C Technologies moved the Series H preferred stock's maturity later, giving the company more time before it comes due. The filing also changes other terms but does not explain their practical effect.

QCLS · Q/C Technologies, Inc.

AI read · Good for QCLS

The AI's read

More time before the preferred shares come due can ease pressure on the company. The filing also changes rules for amending the Series G and Series H terms and ownership limits for PharmaCyte. It does not spell out how those changes affect Q/C Technologies, so the later due date is the clearest company benefit.

PMCB · PharmaCyte Biotech, Inc.

AI read · Neutral

The connection

PharmaCyte agreed to changes in preferred-stock terms, including a later maturity for the Series H shares. The filing does not explain whether the changed rights or later date benefit or cost PharmaCyte.

Get alerts for QCLS

Follow Q/C Technologies, Inc. (QCLS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for QCLS
Free on the App Store and Google Play, or on the web.